Liquid Biopsy Market Research Report
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Biomarker Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Liquid Biopsy Market, By Application
7.1. Liquid Biopsy Market, by Application, 2021-2030
7.1.1. Therapy Selection for Metastatic Breast Cancer (MBS)
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Therapy Selection for Other Metastatic Cancer
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Molecular Health Monitoring
7.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Liquid Biopsy Market, By Sample Type
8.1. Liquid Biopsy Market, by Sample Type, 2021-2030
8.1.1. Blood Sample based
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Urine Sample based
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Other Bio Fluids (Tissue fluids and Saliva) based
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Liquid Biopsy Market, By Biomarker
9.1. Liquid Biopsy Market, by Biomarker, 2021-2030
9.1.1. Circulating Tumor Cells (CTC)
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Circulating Tumor DNA (ctDNA)
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Exosomes
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Liquid Biopsy Market, By Technology
10.1. Liquid Biopsy Market, by Technology, 2021-2030
10.1.1. Multi-gene-parallel Analysis (NGS)
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Single Gene Analysis (PCR Microarrays)
10.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Liquid Biopsy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.1.4. Market Revenue and Forecast, by Technology (2017-2030)
11.1.5. U.S.
11.1.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.1.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.1.6. Rest of North America
11.1.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.1.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.1.6.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.1.6.4. Market Revenue and Forecast, by Technology (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.2.4. Market Revenue and Forecast, by Technology (2017-2030)
11.2.5. UK
11.2.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.2.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.2.6. Germany
11.2.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.6.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.2.6.4. Market Revenue and Forecast, by Technology (2017-2030)
11.2.7. France
11.2.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.7.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.2.7.4. Market Revenue and Forecast, by Technology (2017-2030)
11.2.8. Rest of Europe
11.2.8.1. Market Revenue and Forecast, by Application (2017-2030)
11.2.8.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.2.8.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.2.8.4. Market Revenue and Forecast, by Technology (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.3.4. Market Revenue and Forecast, by Technology (2017-2030)
11.3.5. India
11.3.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.3.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.3.6. China
11.3.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.6.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.3.6.4. Market Revenue and Forecast, by Technology (2017-2030)
11.3.7. Japan
11.3.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.7.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.3.7.4. Market Revenue and Forecast, by Technology (2017-2030)
11.3.8. Rest of APAC
11.3.8.1. Market Revenue and Forecast, by Application (2017-2030)
11.3.8.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.3.8.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.3.8.4. Market Revenue and Forecast, by Technology (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.4.4. Market Revenue and Forecast, by Technology (2017-2030)
11.4.5. GCC
11.4.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.4.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.4.6. North Africa
11.4.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.6.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.4.6.4. Market Revenue and Forecast, by Technology (2017-2030)
11.4.7. South Africa
11.4.7.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.7.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.4.7.4. Market Revenue and Forecast, by Technology (2017-2030)
11.4.8. Rest of MEA
11.4.8.1. Market Revenue and Forecast, by Application (2017-2030)
11.4.8.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.4.8.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.4.8.4. Market Revenue and Forecast, by Technology (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.5.5. Brazil
11.5.5.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.5.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.5.5.4. Market Revenue and Forecast, by Technology (2017-2030)
11.5.6. Rest of LATAM
11.5.6.1. Market Revenue and Forecast, by Application (2017-2030)
11.5.6.2. Market Revenue and Forecast, by Sample Type (2017-2030)
11.5.6.3. Market Revenue and Forecast, by Biomarker (2017-2030)
11.5.6.4. Market Revenue and Forecast, by Technology (2017-2030)
Chapter 12. Company Profiles
12.1. Guardant Health
12.1.1. Company Overview
12.1.2. Application Offerings
12.1.3. Financial PerSample Typeance
12.1.4. Recent Initiatives
12.2. Personal Genome Diagnostics
12.2.1. Company Overview
12.2.2. Application Offerings
12.2.3. Financial PerSample Typeance
12.2.4. Recent Initiatives
12.3. Biocept
12.3.1. Company Overview
12.3.2. Application Offerings
12.3.3. Financial PerSample Typeance
12.3.4. Recent Initiatives
12.4. Adaptive Biotechnologies
12.4.1. Company Overview
12.4.2. Application Offerings
12.4.3. Financial PerSample Typeance
12.4.4. Recent Initiatives
12.5. Cynvenio
12.5.1. Company Overview
12.5.2. Application Offerings
12.5.3. Financial PerSample Typeance
12.5.4. Recent Initiatives
12.6. NeoGenomics Laboratories
12.6.1. Company Overview
12.6.2. Application Offerings
12.6.3. Financial PerSample Typeance
12.6.4. Recent Initiatives
12.7. Qiagen
12.7.1. Company Overview
12.7.2. Application Offerings
12.7.3. Financial PerSample Typeance
12.7.4. Recent Initiatives
12.8. Trovagene
12.8.1. Company Overview
12.8.2. Application Offerings
12.8.3. Financial PerSample Typeance
12.8.4. Recent Initiatives
12.9. RainDance Technologies
12.9.1. Company Overview
12.9.2. Application Offerings
12.9.3. Financial PerSample Typeance
12.9.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms